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Abdominal aortic aneurysms (AAAs) cause death due to complications related to expansion and rupture. 
The underlying mechanisms that drive AAA development remain largely unknown. We recently described 
evidence for a shift toward T helper type 2 (Th2) cell responses in human AAAs compared with stenotic 
atheromas. To evaluate putative pathways in AAA formation, we induced Th1- or Th2-predominant cytokine 
environments in an inflammatory aortic lesion using murine aortic transplantation into WT hosts or those 
lacking the receptors for the hallmark Th1 cytokine IFN-γ, respectively. Allografts in WT recipients devel-
oped intimal hyperplasia, whereas allografts in IFN-γ receptor–deficient (GRKO) hosts developed severe AAA 
formation associated with markedly increased levels of MMP-9 and MMP-12. Allografts in GRKO recipients 
treated with anti–IL-4 antibody to block the characteristic IL-4 Th2 cytokine or allografts in GRKO hosts 
also congenitally deficient in IL-4 did not develop AAA and likewise exhibited attenuated collagenolytic and 
elastolytic activities. These observations demonstrate an important dichotomy between cellular immune 
responses that induce IFN-γ– or IL-4–dominated cytokine environments. The findings establish important 
regulatory roles for a Th1/Th2 cytokine balance in modulating matrix remodeling and have important impli-
cations for the pathophysiology of AAAs and arteriosclerosis.
Introduction
Abdominal aortic aneurysms (AAAs) occur in 5% of individuals 
over the age of 50 and cause approximately 15,000 deaths annually 
due in large part to complications caused by rupture (1). Invasive 
procedures such as surgical or endovascular repair are currently 
the sole therapeutic options for this disease. Despite the demon-
stration of heightened expression of proinflammatory cytokines 
and elastolytic enzymes in human AAA lesions and certain risk fac-
tors associated with AAA disease, the mechanisms underlying AAA 
remain unknown, and lack of satisfactory animal models further 
hampers progress in understanding aneurysm formation.
End-stage AAAs exhibit chronic inflammation and excessive 
extracellular matrix (ECM) catabolism including degradation 
of both collagen and elastin (2, 3); matrix breakdown may thus 
be a primary mechanism underlying aneurysm development (4, 
5). Recent studies confirmed that AAA tissue contains an excess 
of matrix-degrading proteinases, particularly members of the 
MMP family (4–6).
Cytokines regulate MMP expression in vivo and in vitro. 
Previous work showed elevated circulating levels of IL-1, IL-6,   
TNF-α, and IFN-γ in patients with AAA and also implicat-
ed these cytokines in AAA pathogenesis (7). In theory, such 
proinflammatory mediators not only suppress the synthesis of 
procollagens I and III (8) but could also promote elastin and col-
lagen degradation by activation of MMPs and suppression of tis-
sue inhibitor of metalloproteinases (TIMPs). Moreover, MMPs 
can cleave TNF-� precursor (pro–TNF-α) (9) and pro–IL-1β (10) 
to yield their active forms, as well as release cytokines bound to 
the ECM (11), potentially perpetuating a vicious cycle that pro-
motes aneurysm formation.
AAAs contain inflammatory cells including T cells, neutrophils, 
and macrophages, although it remains unclear whether these 
cells simply respond to the pathologic process or incite it. Most 
AAAs occur in the context of atherosclerosis, and atheromata of 
all stages contain CD3+ T lymphocytes bearing markers of both 
helper (CD4) and cytotoxic function (CD8) (12, 13). T cells and 
macrophages may affect atherogenesis by producing various 
cytokines that induce either matrix synthesis or degradation. In 
particular, different T cell subsets secrete IFN-γ or IL-4 that char-
acteristically drive opposing effects on a variety of biological pro-
cesses. CD4+ T helper type 1 (Th1) cells and CD8+ T cytotoxic type 
1 (Tc1) cells produce IFN-γ, IL-2, and TNF, whereas Th2 and Tc2 
cells secrete IL-4, IL-5, and IL-10. T cell responses polarize toward 
a Th1/Tc1 phenotype in the presence of IFN-γ, while IL-4 predis-
poses to Th2/Tc2 T cell responses (14).
Distinct patterns of cytokines produced by T cells might influ-
ence the clinical course of arterial disease. Indeed, previous work 
from our group showed that Th2 cytokines (IL-4, IL-5, or IL-10) 
and Th2-characteristic responses predominate in human AAA 
lesions. In contrast, Th1 responses predominate in stenotic athero-
sclerotic lesions (15). Although the mechanisms that underlie these 
observations remain unknown, it is noteworthy that in vitro, IL-4 
stimulates the production of a variety of ECM proteins (16), while 
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blocking MMP-1 and MMP-9 release from alveolar macrophages 
without altering secretion of corresponding TIMPs (17).
This study used aortic allografts in IFN-γ receptor–deficient 
(GRKO) mice as a novel immunologically driven model of aneu-
rysm formation to test the hypothesis — derived from our obser-
vations in humans — that skewing to Th2-enriched environments 
induces AAA formation. We also explored the underlying molecular 
mechanisms that link Th1/Th2 balances to aneurysm formation.
Results
Allografts in WT and GRKO recipients have IFN-γ– or IL-4–predominant 
cytokine environments, respectively. The aortic allograft model essen-
tially allows the induction of a focal inflammatory response in 
discrete aortic segments. In WT combinations, this inflammation 
results in an intimal hyperplastic lesion without aneurysm forma-
tion (18). To test the role of specific cytokine subsets in the patho-
genesis of AAA in this model, we induced either IFN-γ– or IL-4– 
dominant responses in transplanted BALB/c (B/c, H-2d) aortic 
segments in total allo-mismatched 129SvEv (129Sv, H-2b) hosts. 
Recipients were either WT, which resulted in predominant IFN-γ 
production; or congenitally deficient in GRKO, which resulted in 
IL-4–predominant cytokine expression. Aortic allografts harvested 
one week after transplantation, at the peak of inflammatory cell 
infiltration (18), exhibited significantly greater IL-4 mRNA expres-
sion in the GRKO hosts compared with WT recipients (Figure 1, A 
and B). Other Th2 cytokine mRNAs (IL-10 and IL-15) were mod-
estly increased in allografts in GRKO hosts compared with WT 
recipients (Figure 1A). Western blots (Figure 1C) showed the same 
marked skewing in IL-4 protein production in allografts recovered 
from GRKO versus WT recipients. Although intragraft IFN-γ lev-
els are comparable in WT and GRKO hosts, GRKO inflammatory 
cells cannot respond to IFN-γ signals. Consequently, IL-4 largely 
governs responses to inflammation in GRKO hosts, whereas IFN-γ 
responses direct inflammation in WT hosts.
Figure 1
Aortic allografts from WT or GRKO recipients were har-
vested 1 week after transplantation and were analyzed for 
cytokine expression by RNase protection assay (RPA) (A 
and B) and Western blot for IL-4 (C). (A) Gel image of RPA. 
(B) Histogram of the optical densities from RPA data nor-
malized to GAPDH and averaged for 6 or 7 grafts. (C) Pro-
tein extracts (25 µg/lane) of the aortic grafts of WT or GRKO 
recipients analyzed by Western blot for IL-4.
Figure 2
Aortic allografts from WT (A, C, E, and G) or GRKO (B, D, F, and H) 
recipients 12 weeks after transplantation. (A and B) Representative 
gross appearance of aortas. (C and D) Echoaortograms. (E and F) 
Histologic appearance of transverse sections. (G and H) Elastic van 
Gieson staining (EVG). Analysis of 9–10 aortic transplants from differ-
ent donors yielded similar results. Control (WT) experiments, shown in 
panels A, C, E, and G, did not reveal measurable aneurysm formation 
or elastic tissue degradation. Arrowheads indicate elastic lamellae.research article
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Allografts in GRKO hosts develop aortic aneurysms. Lack of IFN-γ 
receptor in the host resulted in profound aneurysm formation, in 
some cases leading to spontaneous rupture. Figure 2 shows the 
gross appearance (A and B), representative echoaortograms (C and 
D), and the histologic appearance (E and F, same magnification) 
of transverse sections of aortic allografts from WT (A, C, and E) 
or GRKO (B, D, and F) recipients 12 weeks after transplantation. 
The aortic diameter of the allografts of GRKO hosts was approxi-
mately three times larger than that of WT recipients. Aneurysmal 
allografts in GRKO hosts also showed markedly fragmented and 
attenuated elastic laminae in the aortic media (Figure 2H) not seen 
in the WT recipient allografts (Figure 2G).
IL-4 blockade prevents aortic aneurysm formation in allografts in 
GRKO recipients. To examine specifically whether IL-4 blockade 
prevents aneurysm development, we treated GRKO recipients 
of B/c aortic allografts with anti–IL-4 monoclonal antibody 
(11B11). GRKO hosts received 2 mg of anti–IL-4 antibody by 
intraperitoneal injection 1 day before and 1 day after surgery, 
followed by 1 mg antibody per week thereafter (n = 3). We also 
transplanted B/c aortas into mice congenitally double deficient 
in IL-4 and IFN-γ receptor (DKO, n = 6) and harvested the grafts 
12 weeks after transplantation. Aneurysms did not develop in 
aortic allografts from GRKO recipients receiving anti–IL-4 anti-
body (Figure 3A) or in allografts from DKO hosts (Figure 3B). 
Moreover, elastic van Gieson staining showed minimal elastic 
tissue fragmentation in grafts from GRKO hosts treated with 
11B11 (Figure 3C) and no sign of elastolysis in grafts from DK 
O recipients (Figure 3D).
Echoaortograms performed 12 weeks after transplantation and 
just before harvest showed in situ graft diameters of 0.8 ± 0.1 mm 
in isografts (n = 5); 1.0 ± 0.2 mm in WT hosts (n = 9; P = NS vs. 
isografts); 2.9 ± 0.8 mm in GRKO hosts (n = 10; P < 0.0001 vs. 
WT); 1.3 ± 0.1 mm in GRKO hosts receiving anti–IL-4 treatment 
(n = 3; P = 0.005 vs. GRKO); and 1.0 ± 0.2 mm in DKO hosts (n = 6;   
P < 0.0001 vs. GRKO). Our results indicate that the presence of IL-4   
predominance induces aortic aneurysm formation (Figure 3E) and 
that IL-4 blockade prevents aneurysm formation.
Aneurysm formation does not result from increased blood pressure. To 
examine whether IL-4 elaboration or blockade affected systemic 
blood pressure (and thereby influenced AAA formation), we mea-
sured the recipient systolic arterial pressure 12 weeks after trans-
plantation by a tail cuff. Blood pressure in all transplant groups 
was similar: 106 ± 18 mmHg in WT; 101 ± 13 mmHg in GRKO; 
and 96 ± 11 mmHg in DKO (P = NS).
Increased mRNA expression of elastolytic MMPs mRNA correlates 
with allograft aneurysm formation in GRKO recipients. The ECM 
protein elastin consists of highly cross-linked, hydropho-
bic tropoelastin monomers that confer resilience to the elas-
tic fibers. The hydrophobicity and extensive cross-linking of 
tropoelastin result in an insoluble fiber that resists proteolysis. 
Under normal conditions, elastin has minimal turnover (19). 
Nevertheless, destruction of elastic fibers characterizes certain 
pathological situations such as AAAs (20).
The ability of certain MMPs, e.g., MMP-2, -3, -9, and -12, to 
degrade elastin may have particular relevance to AAA formation, 
as human AAAs exhibit abundant MMP-2 and MMP -9 expression 
(21, 22) and, in some cases, excessive MMP-1 and MMP-3 (4–6). 
In experimental models, targeted disruption of MMP-9 results 
in decreased elastin fiber degradation after elastase perfusion in 
mouse aortas and suppresses the subsequent development of aor-
tic aneurysms (23). The other elastolytic MMPs such as matrilysin 
(MMP-7) (24) and macrophage metalloelastase (MMP-12) (25, 26) 
may play even greater roles in very large aneurysms.
In addition to the MMPs, AAAs contain excessive serine 
proteases such as plasmin, as well as elevated plasminogen acti-
vators (PAs) (i.e., urokinase PA, uPA; and tissue PA, tPA), com-
pared with normal aortic tissue (4, 5). Cysteine proteinases such 
as cathepsin-L, -S, and -K or serine proteinases such as neutro-
phil elastases have elastinolytic potential (27) and may also con-
tribute to AAA formation.
To identify which elastinolytic or collagenolytic enzymes con-
tribute to elastin degradation and AAA formation in grafts in 
GRKO mouse hosts, we performed LightCycler-based real-time 
PCR using cDNA prepared from total RNA extracted from aortic 
allografts one week after transplant at the peak of inflammatory 
cell infiltration (18). We examined MMP-1 through MMP-24,   
TIMP-1 through TIMP-4, cathepsin-L, -S, and -K, neutrophil 
elastase, uPA, and tPA. MMP-2, -3, -9, -12, -13, -15, and -19 
mRNA expression all increased significantly in allografts from 
GRKO recipients with parallel increases in TIMP-1, TIMP-2, and 
TIMP-3 compared with grafts in either WT or DKO hosts (n = 6 
for each; Figure 4). Allografts from DKO had significantly lower 
MMP-10 mRNA levels than allografts from GRKO recipients; 
Figure 3
Aortic allografts from GRKO recipients treated with anti–IL-4 antibody 
(A and C) or from DKO recipients (B and D) harvested at 12 weeks 
after transplantation. (A and B) Representative histologic appearance 
of transverse sections. (C and D) Elastic van Gieson staining. (E) 
Analysis of aortic diameter from the isograft (Iso) (n = 5), WT recipi-
ent allografts (n = 9), GRKO recipient allografts (n = 10), allografts in 
GRKO recipients with anti–IL-4 antibody (11B11) treatment (n = 3), 
and DKO (n = 6) recipient allografts 12 weeks after transplantation.   
*P < 0.01 vs. GRKO; **P < 0.0001 vs. GRKO.research article
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expression of mRNA encoding the other proteases did not differ 
between groups (data not shown).
Elevated enzymatic activities for MMP-12 in allografts in GRKO hosts. 
To test formally whether the elevated MMP mRNA resulted in 
increased functional enzymatic activity, we performed West-
ern blot analysis, elastase colorimetric assay, and zymography. 
Western blot analysis demonstrated markedly increased expres-
sion of MMP-12 in allografts from GRKO hosts compared with 
allografts from WT and DKO recipients (Figure 5A). At one 
week, aortic allografts in GRKO recipients had significantly 
greater elastase activity (6.61 ± 1.60 µU/g; n = 6) relative to WT 
hosts (1.75 ± 0.41 µU/g; n = 6; P < 0.0001) and DKO recipients 
(0.61 ± 0.15 µU/g; n = 6; P < 0.0001). Immunoprecipitation with 
anti–MMP-12 antibody of the proteins recovered from allografts 
in GRKO hosts removed the majority of the elastolytic activity 
with residual elastase colorimetric assay activity of 0.04 ± 0.05 
µU/g (P < 0.0001 vs. nonimmunoprecipitated proteins from 
aortic grafts in GRKO hosts; n = 6; Figure 5B). Gelatin zymog-
raphy (Figure 5C) and casein zymography (Figure 5D) corrobo-
rated these results; increased activities corresponded to MMP-2, 
MMP-9, and MMP-12 proteases, as indicated. The same amounts 
of proteins loaded in the gels suggests much higher MMP-12 
activities than MMP-9 in GRKO recipient allografts.
The majority of the graft-infiltrating cells during aneurysm formation 
are macrophages. A number of cell types including endothelial 
cells, medial smooth muscle cells, and adventitial connective 
tissue cells might contribute to the local pool of MMPs in vas-
cular tissues (28). Monocyte-derived macrophages in particular 
can express abundant active MMPs (4, 5, 29), especially MMP-9 
and MMP-12 in diseased tissues. MMP activity depends on con-
trol at the transcriptional level by cytokines, on activation of 
the proenzyme forms of the MMPs, and on the local concentra-
tions of TIMPs (28, 30). We observed medial elastinolysis in the 
allografts in GRKO hosts within 1–4 weeks of transplantation 
(18), when the majority of the graft-infiltrating cells consist of 
CD11b+ macrophages (Figure 6, B and D), with a lesser contri-
bution of CD4+ T cells (Figure 6, A and C) and CD8+ T cells 
(data not shown). Immunoreactive MMP-12 (Figure 6, F and H) 
colocalized predominantly with CD11b+ cells (Figure 6, E and 
G), which suggests that infiltrating macrophages provide much 
of the MMP-12 in developing AAA.
IL-4 augments and IFN-γ diminishes MMP-12 mRNA expression in 
macrophages. To examine whether IL-4 and IFN-γ can directly mod-
ulate MMP-12 expression in macrophages, we cultured bone mar-
row–derived macrophages from WT and GRKO mice in the pres-
ence of IL-4, IFN-γ, and/or anti–IL-4 antibody. Both conventional 
Figure 4
Metalloproteinase expression during AAA development. The MMP mRNA levels of aortic allografts from WT (white bars), GRKO (black bars), or 
DKO (gray bars) recipients (n = 6, each). Total RNA was extracted from the aortic allografts and first-strand cDNA generated by reverse transcrip-
tion was subjected to real-time quantitative PCR with the LightCycler. Data represent the mean ± SEM of six determinations of the percentage 
of mRNA copies relative to untreated growing cells. *P < 0.05; **P < 0.01; ***P < 0.001.research article
304  The Journal of Clinical Investigation      http://www.jci.org      Volume 114      Number 2      July 2004
PCR (23 cycles) with subsequent gel electrophoresis (Figure 7A) 
and real-time quantification of MMP-12 gene copy number using 
LightCycler (Figure 7B) were performed on cDNA from total RNA 
extracted after 18 hours of macrophage culture. IL-4 increased 
MMP-12 mRNA expression, and anti–IL-4 antibody abolished this 
effect. Moreover, IFN-γ decreased IL-4–induced MMP-12 mRNA 
expression in WT macrophages but did not inhibit MMP-12   
expression in GRKO macrophages (data not shown). MMP-9 
mRNA expression exhibited the same responses to IFN-γ and IL-4 
as MMP-12 (data not shown).
Discussion
This study sought to examine the relative effects on arterial dis-
ease of a prototypical “proinflammatory cytokine” (e.g., IFN-γ 
from Th1 cells) versus an “anti-inflammatory cytokine” (e.g., IL-4   
from Th2 cells). This study showed that IL-4–driven inflamma-
tion in aortic transplants induced severe AAA formation associat-
ed with markedly increased expression of MMP-9 and MMP -12;   
blockade of IL-4 effects via anti–IL-4 or congenital absence of 
IL-4 reduced AAA formation with associated decreases in elastic 
tissue fragmentation and in MMP-9 and MMP-12 expression.
Previous work found elevated proinflammatory cytokines 
or chemokines (e.g., IL-1, IL-6, IL-8, TNF-α, IFN-γ, monocyte 
chemoattractant protein-1 [MCP-1]) systemically or in human 
AAA tissue obtained at surgery, implicating these cytokines in AAA 
pathogenesis (7). Atherosclerotic lesions frequently associate with 
AAAs, and similar risk factors for atherosclerosis and AAA forma-
tion have been identified. However, differences in proteolytic activ-
ities and disparities in the characteristics of patients that develop 
AAA versus stenotic lesions suggest that AAA formation does not 
necessarily require preexisting atherosclerosis (31). Moreover, our 
previous work showed that Th2 cytokines and responses predomi-
nated in human AAA lesions, while Th1 responses predominated 
in stenotic atherosclerotic lesions (15).
Figure 5
Western blot for MMP-12, elastase colorimetric assay, and gelatin and 
casein zymography. (A) Representative gel image of Western blot 
analysis. Protein extracts (20 µg/lane) of the aortic grafts of WT (n = 6),   
GRKO (n = 6), or DKO (n = 6) recipients analyzed by Western blot for 
MMP-12. The gel images represent qualitatively similar results. (B) 
The elastase colorimetric assay shows significantly greater elastase 
activity in the proteins extracted from allografts in GRKO hosts (n = 6)   
compared with proteins extracted from allografts in WT (n = 6) or DKO 
(n = 6) hosts. After anti–MMP-12 immunoprecipitation (IP) (n = 6), the 
proteins from allografts from GRKO recipients had significantly reduced 
elastase activity, which indicates that the majority of elastolytic activ-
ity in those allografts derives from MMP-12. Bar shows mean ± SEM;   
*P < 0.0001. (C and D) Representative gel images of gelatin zymogram 
(C) and casein zymogram (D). Protein extracts (20 µg/lane) of the 
aortic grafts of WT (n = 6), GRKO (n = 6), or DKO (n = 6) recipients 
analyzed by (C) gelatin- or (D) casein-zymogram for MMPs. The gel 
images represent qualitatively similar results. We could detect only 92 
kDa and 72 kDa active bands from GRKO recipient allografts in the 
gelatin zymogram (C) and only 20 kDa active band from GRKO recipi-
ent allografts in the casein zymogram (D).
Figure 6
Representative immunohistochemistry of CD4+ (A and C) and CD11b+ 
(B and D) cells in allografts from GRKO recipients harvested 4 weeks 
after transplantation (n = 6). Boxed area in A or B (original magnifica-
tion, ×100) is enlarged in C or D (original magnification, ×400), respec-
tively. The majority of the graft infiltrating cells, especially adjacent 
to degraded elastic lamellae, consisted of CD11b+ macrophages. 
Expression of MMP-12 (F and H) colocalized with CD11b+ cells (E 
and G) in allografts from GRKO recipients harvested 4 weeks after 
transplantation (n = 6).research article
  The Journal of Clinical Investigation      http://www.jci.org      Volume 114      Number 2      July 2004  305
Elastase perfusion (23), angiotensin II infusion (32), or local 
treatment with CaCl2 (33) result in aneurysm formation in ani-
mals. However, no prior studies have used animals with specific 
chemokine or cytokine deficiencies to define the function of these 
mediator proteins in aneurysm formation.
The current study used allo-mismatched aortic transplanta-
tion to induce local inflammation in aortic segments with WT 
or GRKO animals to elicit IFN-γ– or IL-4–predominant respons-
es, respectively. Death of medial smooth muscle cells per se does 
not cause aneurysm formation (18). Although acute rejection 
causes virtually complete medial smooth muscle cell death in 
allo-mismatched WT recipient aortic allografts, they do not 
develop aneurysms and in fact develop intimal hyperplasia (18). 
Strikingly, GRKO recipient allografts developed profound aor-
tic aneurysms with degradation of the medial elastic laminae 
similar to that seen in human AAAs. These results demonstrate 
in vivo that specific blockade of IFN-γ signaling (Th1 depletion) 
and/or augmented IL-4 (Th2 predominance) can directly modu-
late elastolytic enzymes and yield degradation of elastic laminae 
of the arterial tunica media.
In humans, aneurysms can form because of atherosclerosis, focal 
loss of elastic and smooth muscle fibers (cystic medial degenera-
tion, e.g., due to hypertension and Marfan syndrome), congeni-
tal defects in the vascular wall (e.g., berry aneurysms), and/or 
infections (e.g., luetic aneurysms). The pathologic characteristics 
of AAA classically consist of inflammatory infiltrates with elas-
tin and collagen (types I and III) degradation, resulting in vessel 
wall expansion and potentially rupture. All types of AAAs require 
degradation or loss of elastic fibers in the media. Perturbations 
in either synthesis or degradation could conceivably diminish the 
elastin and collagen fibers. However, mRNA levels of procollagen 
and tropoelastin from aortic allografts one week after transplant 
showed no differences in expression among WT, GRKO, and DKO 
recipient allografts (data not shown).
MMP-9 and MMP-12 degrade elastin efficiently, and human 
AAA lesions contain these MMPs, as well as MMP-1, MMP-3, and 
MMP-13. Activation of latent MMPs requires proteolytic cleav-
age of a region that unmasks the active zinc-containing catalyt-
ic site. In addition, MMP activity also depends on the level of 
endogenous inhibitors such as TIMPs. Serine proteases such as 
plasmin, uPA, and tPA also localize in AAAs and correlate with 
macrophage infiltration (34). Plasmin and uPA activate MMP-3, 
MMP-12, and MMP-13, and since absence of uPA in mice pro-
tects from rupture of aortic aneurysms, uPA may regulate the 
downstream cascade of MMP effectors (35).
This study used real-time PCR with cDNA extracted from the 
early stages of aortic allografts with or without AAA to assess 
mRNAs that encode multiple MMPs and elastolytic enzymes. We 
also measured the elastolytic activities using protein extracted 
from the AAA tissue. The results suggest that relatively few MMPs 
contribute to aortic expansion under these conditions. Increased 
TIMP-1, TIMP-2, and TIMP-3 mRNA expression paralleled 
MMP-9, MMP-12, and MMP-13 mRNA elevation, with higher 
mRNA expression in GRKO allografts and lower mRNA expres-
sion in DKO allografts. Thus, increased TIMP activity alone does 
not suffice to modulate MMP degradation. Allografts in GRKO 
hosts showed markedly higher elastolytic activities relative to aor-
tic grafts in WT and DKO recipients, and this elastolytic activity 
diminished markedly after MMP-12 immunoprecipitation.
Th2 cytokines are usually considered largely anti-inflammatory, 
although Th2-dominated inflammatory responses clearly drive 
allergic asthma, as well as some proinflammatory activity in other in 
vivo models (36). While IL-4 suppresses some MMP protein expres-
sion in monocytes (37), other reports demonstrated that IL-13   
(originally described as an IL-4–like cytokine) potently induces 
MMP-2, -9, -12, -13, and –14 (38). We also previously reported an 
apparently paradoxical role of IL-10 in exacerbating allograft arte-
riosclerosis (39). The current work clearly supports a role for IL-4 
in increasing selected elastolytic activities. At the same time, this 
study shows that IFN-γ can protect against augmented elastase 
activities that induces aneurysm formation. Indeed, we found 
that total allo-mismatched aortic allografts of IFN-γ–deficient 
recipients developed aneurysms to the same extent as allografts in 
GRKO recipients (data not shown).
Various cytokines differentially affect protease activity. Thus, 
earlier studies demonstrated an important role for MMP-9 
in AAA development and implicated proinflammatory (Th1) 
cytokines in elevating macrophage MMP expression. Lung-
specific IFN-γ overexpression in transgenic mice also induced 
MMP-12 and stimulated the release of MMP-9, leading to pul-
monary emphysema (40). However, IFN-γ has inhibitory effects 
on MMP-9 in human monocytes and macrophages (41) and in 
murine peritoneal macrophages (42), as well as on MMP-12 in 
murine macrophages (43).
Atherosclerosis is also a major risk factor for AAA formation, 
and IFN-γ potentiates atherosclerosis (44); moreover, IFN-γ is 
necessary for inducing transplant-associated arteriosclerosis 
(45). The current study contradicts earlier results suggesting 
that IFN-γ is important for AAA development. However, in those 
models, atherosclerosis requires inflammatory cell recruitment, 
Figure 7
Conventional RT-PCR (A) and real-time PCR (B) for MMP-12 from WT 
bone marrow–derived macrophages incubated 18 hours with IL-4 (10 
ng/ml), IFN-γ (500 U/ml), and/or anti–IL-4 antibody (5 µg/ml, 11B11). 
IL-4 augmented and IFN-γ inhibited MMP-12 mRNA expression of the 
WT macrophages. In addition, 11B11 inhibited IL-4–induced augmen-
tation of MMP-12 mRNA expression by the WT macrophages. Bar 
shows mean ± SEM (n = 6, each). *P < 0.0001.research article
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and in the absence of IFN-γ, this inflammation is reduced. In the 
current work, we use an alloresponse to drive the local inflam-
matory cell recruitment and can do so while formally testing 
the relative roles of Th1 and Th2 cytokines. Although some of 
the differences between atherosclerosis and alloresponse AAA 
development may be due to the specific models, it is notewor-
thy that current results mirror the cytokine profiles described in 
human AAAs (15). We therefore believe that IFN-γ is capable of 
attenuating AAA lesions.
While the model used here involved major histocompatibility 
mismatched allografts, there appears to be a striking similarity 
between our results and recent work on viral infections in large 
elastic arteries; increased transmural arterial inflammation 
occurs in GRKO mice infected with CMV (46) or γ-herpesvirus 68 
(47), suggesting that the elastic media of great vessels may be an 
immune-privileged site, perhaps with privilege preserved in part 
by IFN-γ. The current study focused on Th1/Th2 cytokine milieu 
on AAA using allogeneic responses based on our previous find-
ings of Th2-predominant cytokine expression in the human AAA 
lesions and did not explore the effects of atherosclerosis generally 
observed in human AAA lesions. It is possible that human ath-
erosclerotic lesions need some additional (perhaps idiosyncratic) 
Th2-predominant inflammatory responses to develop aneurysm 
formation rather than Th1-dominated obstructive lesions. Fur-
ther study remains to elucidate such triggers.
This study demonstrates that blockade of IFN-γ signaling 
pathways and subsequent IL-4–mediated events induced AAA 
formation associated with augmented elastolytic activity primar-
ily due to increased MMP-12 expression. The majority of inflam-
matory cells at the early stage of AAA consist of macrophages 
that also express MMP-12 as shown by immunohistochemical 
staining. In addition, in vitro macrophage cultures show aug-
mented expression of elastolytic MMP-12 in the presence of IL-4, 
an effect inhibited by coadministration of IFN-γ. These findings 
identify IL-4 as an important stimulus to AAA formation and 
suggest that IFN-γ can potentially act to attenuate collagenolytic 
and elastolytic activity. Our results furnish new insight into the 
mechanisms of aneurysmal disease and suggest that IL-4 block-
ade or IFN-γ activation may inhibit the formation and/or expan-
sion of arterial aneurysms.
Methods
Mice. The studies reported here conform to the principles outlined 
by the Animal Welfare Act and the NIH guidelines for the care 
and use of animals in biomedical research. WT 129SvEv and B/c 
mice were obtained from Taconic Farms Inc. (Germantown, New 
York, USA). 129Sv(GRKO) mice were obtained from The Jackson 
Laboratory (Bar Harbor, Maine, USA). The generation and the 
basic characteristics of the mutant mouse strain (129SvEv) with 
a disruption in the gene encoding the α-chain of the IFN-γ recep-
tor have been described (48). C57BL/6 IL-4–deficient mice were 
obtained from The Jackson Laboratories and crossed to GRKO 
mice to obtain DKO mice (back-crossed onto 129Sv, for at least 4 
generations). The mice were maintained in the Harvard Medical 
School animal facilities on acidified water. Sentinel animals in 
the same room were surveyed serologically and were consistently 
negative for all viral pathogens.
Aortic transplantation. WT B/c, WT 129Sv, and 129Sv(GRKO) male 
mice aged 8–12 weeks and weighing 20–25 g were used as recipients 
or donors. Aortic transplantation was performed as described (18). 
No immunosuppressive medication was used. Grafts that became 
occluded within the first 10 days were considered technical failures 
and were excluded from further consideration. The graft success 
rate was more than 90%.
Noninvasive blood pressure measurements. Blood pressure and heart 
rate were measured noninvasively using the Visitech BP-2000 
Blood Pressure Analysis System (Visitech Systems, Apex, North 
Carolina, USA). To ensure accuracy and reproducibility, the mice 
were trained for 1 week prior to the experiment, and measure-
ments were taken at the same time each day. Unanesthetized mice 
were placed on the specimen platform, and their tails were placed 
through tail cuffs and secured in place with tape. Following a 15-
minute warm-up period, 10 preliminary cycles were performed 
to allow the mice to adjust to the inflating cuff. For each mouse, 
10 cycles were recorded for each time point, and the data for each 
group of mice were combined.
Quantification of mRNA using LightCycler-based real-time, quantitative 
RT-PCR. Messenger RNA levels were quantitated for a variety of 
MMPs from aortic allografts harvested one week after transplanta-
tion or from in vitro–cultured marrow-derived macrophages using 
LightCycler-based real-time PCR and quantitative RT-PCR protocols 
using the LightCycler-DNA Master SYBR Green I kit (Roche Molecu-
lar Biochemicals, Mannheim, Germany), as described previously (49). 
Total RNA was extracted from aortic grafts using Trizol (Invitrogen 
Corp., Carlsbad, California, USA) and purified with RNeasy kit (Qia-
gen Inc., Valencia, California, USA); cDNA was synthesized with a 
First-Strand cDNA Synthesis Kit followed by DNase treatment 
(Invitrogen). TaqStart antibody (CLONTECH, Palo Alto, California, 
USA) was used to prevent generation of nonspecific amplification 
products. Quantitation was performed using primers designed by 
Primer3 program (www.genome.wi.mit.edu/cgi-bin/primer/prim-
er3_www.cgi), and PCR reactions were examined by agarose gel elec-
trophoresis to confirm melting curve results. We devised methods 
suitable for quantitation of the following mRNA: MMP-1, -2, -3,   
-7, -9, -12, -13, -15, -17, and –19; TIMP-1, -2, -3, and –4; neutrophil 
elastase; cathepsins-L, -S, and –K; uPA; and tPA. Fluorescence data 
were quantitatively analyzed using serially diluted control samples 
to produce standard curves. Data represent the mean ± SEM of six to 
seven determinations of the percentage of mRNA copies relative to 
the control WT recipient allografts, which was set to 100%.
Immunoblotting. Aortic grafts from WT (n = 6), GRKO (n = 6), 
and DKO (n = 6) recipients were harvested and homogenized in 50 
mmol/l Tris/HCL (Sigma-Aldrich, St. Louis, Missouri, USA) (pH 
8.0) containing 0.5% Triton-X100 (Sigma-Aldrich) and centrifuged 
(500 g for 30 minutes at 4°C). Samples were centrifuged at 3,000 g 
for 30 minutes, and the protein concentration for each tissue extract 
was determined using the bicinchoninic acid (BCA) assay (Pierce, 
Rockford, Illinois, USA). Total proteins (20 µg/well) were separated 
by standard SDS-PAGE and blotted to polyvinylidene difluoride 
membranes (Bio-Rad, Hercules, California, USA) using a semi-
dry blotting apparatus (3 mA/cm2, 60 min; Bio-Rad). Blots were 
blocked, and primary and secondary antibodies were diluted in 5% 
defatted dry milk/PBS/0.1% Tween 20 (Sigma-Aldrich). Primary rab-
bit anti-mouse MMP-12 antibodies (Santa Cruz Biotechnology Inc., 
Santa Cruz, California, USA) were applied at 2 µg/ml. After 1 hour 
of incubation with the primary antibody, blots were washed 3 times 
(PBS/0.1% Tween 20) and the relevant secondary, peroxidase-conju-
gated antibody (500 ng/ml, Jackson Immunoresearch, West Grove, 
Pennsylvania, USA) was added for another hour. Finally, the blots 
were washed (20 min, PBS/0.1% Tween 20) and immunoreactive research article
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proteins visualized using the SuperSignal West Femto kit (Pierce). 
Densitometric analysis of immunoreactive bands employed Image-
Pro software (Media Cybernetics, Silver Spring, Maryland, USA) 
applied to digital images of the Western blots. We performed quan-
titative immunoblots using equal starting amounts of protein.
Zymography. Aortic grafts from WT (n = 6), GRKO (n = 6), and DKO 
(n = 6) recipients were harvested and homogenized in 50 mmol/l 
Tris/HCL (pH 8.0) containing 0.5% Triton-X100 and centrifuged 
(500 g for 30 minutes at 4°C). Samples were centrifuged at 3,000 g 
for 30 minutes, and the protein concentration for each tissue extract 
was determined using the BCA assay (Pierce). Total proteins (20 µg/
well) were separated under nonreducing conditions by SDS-PAGE 
containing 1 mg/ml gelatin or casein (Bio-Rad). After electrophore-
sis, the proteins were renatured by soaking the gels in renaturation 
buffer (Bio-Rad). Gels were stained with Coomassie brilliant blue 
R250 and then destained in 25% methanol/20% acetic acid.
Colorimetric assay of elastase. The same protein samples as pre-
pared for immunoblotting were used for enzymatic analysis by 
colorimetry. The elastase assay is based on the specific hydroly-
sis of MeOSuc-Ala-Ala-Pro-Val-p-nitroanilide (Calbiochem, San 
Diego, California, USA) by elastase, resulting in the release of the 
p-nitroaniline (pNA) moiety (50). Each 20 µg of sample was incu-
bated with 20 µg of substrate on a 96-well flat-bottom microplate 
(Corning Inc., New York, New York, USA) at 37°C for 60 minutes, 
and released pNA (emission at 405 nm) was measured. The activ-
ity of the samples was calculated relative to an elastase type III   
(4 U/mg, Sigma-Aldrich) standard curve.
We also performed elastase colorimetric assays using the protein 
samples from GRKO recipient allografts following anti–MMP-12 
immunoprecipitation. The protein samples of the GRKO recipient 
allografts were incubated with anti–MMP-12 antibody (2 µg/ml) 
for 18 hours at 4°C, followed by incubation with immobilized pro-
tein G for 30 minutes at 4°C using an Immunoprecipitation Kit 
(Pierce). Samples were centrifuged, and the buffer was collected 
and adjusted to pH 8.0. The protein concentration was normalized 
using the BCA assay before the elastase assay.
Immunohistochemistry. Immunohistochemistry was performed to 
evaluate the relative percentages of CD4-, CD8-, and CD11b-posi-
tive inflammatory cells in the cardiac allografts as described pre-
viously (51). For MMP-12 staining, 5 µm cryosections were fixed 
in 5% paraformaldehyde before preincubation with 0.5% H2O2. 
Slides were incubated with 10% normal goat serum and stained 
with purified monoclonal anti–MMP-12 antibodies (2 µg/ml) or 
negative control antisera (rabbit IgG, 2 µg/ml, BD Biosciences 
– Pharmingen, San Diego, California, USA). Sections were incu-
bated with biotinylated goat anti-rabbit IgG antibodies (1 µg/ml, 
Southern Biotechnology Associates Inc., Birmingham, Alabama, 
USA), followed by streptavidin-peroxidase (DAKO, Carpinteria, 
California, USA). Antibody binding was visualized with 3-amino-
9-ethyl carbazole (DAKO), and nuclei were counterstained with 
Gill’s hematoxylin (Sigma-Aldrich).
Statistical analysis. Comparisons between groups was performed 
using a two-way ANOVA with the post-hoc test. Since the AAA 
lesion area was not normally distributed, the Mann-Whitney U 
test was used to evaluate differences in aortic size. Statview 4.5 for 
Macintosh (Abacus Concepts Inc., Berkeley, California, USA) was 
used for all statistical calculations.
Acknowledgments
This study was supported by NIH grants RO1 HL-43364 (to P. 
Libby and R.N. Mitchell), GM-67049 (to R.N. Mitchell and K. 
Shimizu), and HL-67283 (to K. Shimizu and R.N. Mitchell) and a 
Roche Organ Transplantation Research Foundation grant award 
(K. Shimizu), a Harvard Medical School BWH (Brigham and Wom-
en’s Hospital) Fellowship Award (K. Shimizu), and a Grant-in-Aid 
for Scientific Research from the Ministry of Education, Culture, 
Sports, Science, and Technology of Japan (to M. Shichiri). We 
thank E. Shvartz, J. Allen, and E. Simon-Morrissey for their tech-
nical expertise and K. Williams for her editorial expertise.
Received for publication August 20, 2003, and accepted in revised 
form May 4, 2004.
Address correspondence to: Koichi Shimizu, Cardiovascular 
Division, Department of Medicine, Brigham and Women’s Hos-
pital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB7, 
Boston, Massachusetts 02115, USA. Phone: (617) 525-4556; Fax: 
(617) 525-4380; E-mail: ksmz@rics.bwh.harvard.edu.
  1. Hallett, J.W., Jr. 2000. Management of abdominal 
aortic aneurysms. Mayo Clin. Proc. 75:395–399.
  2. Glagov, S. 1977. Morphology of collagen and elas-
tin fibers in atherosclerotic lesions. Adv. Exp. Med. 
Biol. 82:767–773.
  3. Campa, J.S., Greenhalgh, R.M., and Powell, J.T. 
1987. Elastin degradation in abdominal aortic 
aneurysms. Atherosclerosis. 65:13–21.
  4. Newman, K.M., et al. 1994. Matrix metalloproteinases 
in abdominal aortic aneurysm: characterization, 
purification, and their possible sources. Connect.  
Tissue Res. 30:265–276.
  5. Thompson, R.W., and Parks, W.C. 1996. Role of 
matrix metalloproteinases in abdominal aortic 
aneurysms. Ann. N. Y. Acad. Sci. 800:157–174.
  6. Knox, J.B., Sukhova, G.K., Whittemore, A.D., and 
Libby, P. 1997. Evidence for altered balance between 
matrix metalloproteinases and their inhibitors in 
human aortic diseases. Circulation. 95:205–212.
  7. Juvonen, J., et al. 1997. Elevated circulating levels of 
inflammatory cytokines in patients with abdomi-
nal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 
17:2843–2847.
  8. Amento, E.P., Ehsani, N., Palmer, H., and Libby, 
P. 1991. Cytokines and growth factors positively 
and negatively regulate interstitial collagen gene 
expression in human vascular smooth muscle cells. 
Arterioscler. Thromb. 11:1223–1230.
  9. Chandier, S., Cossins, J., Lury, J., and Wells, G. 1996. 
Macrophage metalloelastase degrades matrix and 
myelin proteins and processes a tumor necrosis 
factor-alpha fusion protein. Biochem. Biophys. Res. 
Commun. 228:421–429.
 10. Schonbeck, U., Mach, F., and Libby, P. 1998. 
Generation of biologically active IL-1b by matrix 
metalloproteinases: a novel caspase-1-indepen-
dent pathway of IL-1b processing. J. Immunol. 
161:3340–3346.
 11. Gilat, D., Cahalon, L., Hershkoviz, R., and Lider, O. 
1996. Interplay of T cells and cytokines in the con-
text of enzymatically modified extracellular matrix. 
Immunol. Today. 17:16–20.
 12. Watanabe, T., Shimokama, T., Haraoka, S., and 
Kishikawa, H. 1995. T lymphocytes in atheroscle-
rotic lesions. Ann. N. Y. Acad. Sci. 748:40–55.
 13. Hansson, G.K., Holm, J., and Jonasson, L. 1989. 
Detection of activated T lymphocytes in the human 
atherosclerotic plaque. Am. J. Pathol. 135:169–175.
 14. Elser, B., et al. 2002. IFN-gamma represses IL-4   
expression  via  IRF-1  and  IRF-2.  Immunity. 
17:703–712.
 15. Schonbeck, U., Sukhova, G.K., Gerdes, N., and 
Libby, P. 2002. Th2 predominant immune respons-
es prevail in human abdominal aortic aneurysm. 
Am. J. Pathol. 161:499–506.
 16. Postlethwaite, A., Holness, M.A., Katai, H., and Rag-
how, R. 1992. Human fibroblasts synthesize elevat-
ed levels of extracellular matrix proteins in response 
to interleukin 4. J. Clin. Invest. 90:1479–1485.
 17. Lacraz, S., et al. 1992. Suppression of metal-
loproteinase  biosynthesis  in  human  alveolar 
macrophages  by  interleukin-4.  J. Clin. Invest. 
90:382–388.
 18. Shimizu, K., et al. 2001. Host bone-marrow cells are 
a source of donor intimal smooth- muscle-like cells 
in murine aortic transplant arteriopathy. Nat. Med. 
7:738–741.
 19. Shapiro, S.D., Endicott, S.K., Province, M.A., Pierce, 
J.A., and Campbell, E.J. 1991. Marked longevity of 
human lung parenchymal elastic fibers deduced 
from prevalence of D-aspartate and nuclear weapons-
related radiocarbon. J. Clin. Invest. 87:1828–1834.
 20. Thompson, R.W., et al. 1995. Production and local-
ization of 92-kilodalton gelatinase in abdominal 
aortic aneurysms. An elastolytic metalloproteinase 
expressed by aneurysm-infiltrating macrophages. 
J. Clin. Invest. 96:318–326.
 21. Vine, N., and Powell, J.T. 1991. Metalloproteinases research article
308  The Journal of Clinical Investigation      http://www.jci.org      Volume 114      Number 2      July 2004
in degenerative aortic disease. Clin. Sci. 81:233–239.
 22. McMillan, W.D., et al. 1995. In situ localization 
and quantification of mRNA for 92-kD type IV 
collagenase and its inhibitor in aneurysmal, occlu-
sive, and normal aorta. Arterioscler. Thromb. Vasc. 
Biol. 15:1139–1144.
 23. Pyo, R., et al. 2000. Targeted gene disruption of 
matrix metalloproteinase-9 (gelatinase B) sup-
presses development of experimental abdominal 
aortic aneurysms. J. Clin. Invest. 105:1641–1649.
 24. Murphy, G., Cockett, M.I., Ward, R.V., and Docherty, 
A.J. 1991. Matrix metalloproteinase degradation of 
elastin, type IV collagen and proteoglycan. A quan-
titative comparison of the activities of 95 kDa and 
72 kDa gelatinases, stromelysins-1 and -2 and 
punctuated metalloproteinase (PUMP). Biochem. J. 
277:277–279.
 25. Shapiro, S.D., Kobayashi, D.K., Pentland, A.P., 
and Welgus, H.G. 1993. Induction of macrophage 
metalloproteinases by extracellular matrix. Evi-
dence for enzyme- and substrate-specific responses 
involving prostaglandin-dependent mechanisms. 
J. Biol. Chem. 268:8170–8175.
 26. Curci, J.A., Liao, S., Huffman, M.D., Shapiro, S.D., 
and Thompson, R.W. 1998. Expression and local-
ization of macrophage elastase (matrix metallopro-
teinase-12) in abdominal aortic aneurysms. J. Clin. 
Invest. 102:1900–1910.
 27. Punturieri, A., et al. 2000. Regulation of elastino-
lytic cysteine proteinase activity in normal and 
cathepsin K-deficient human macrophages. J. Exp. 
Med. 192:789–799.
 28. Nagase, H. 1997. Activation mechanisms of matrix 
metalloproteinases. Biol. Chem. 378:151–160.
 29. Freestone, T., et al. 1995. Inflammation and matrix 
metalloproteinases in the enlarging abdominal 
aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 
15:1145–1151.
 30. Libby, P., and Lee, R.T. 2000. Matrix matters. Circu-
lation. 102:1874–1876.
 31. Tilson, M.D. 1992. Aortic aneurysms and athero-
sclerosis. Circulation. 85:378–379.
 32. Daugherty, A., Manning, M.W., and Cassis, L.A. 
2000. Angiotensin II promotes atherosclerotic 
lesions and aneurysms in apolipoprotein E-defi-
cient mice. J. Clin. Invest. 105:1605–1612.
 33. Longo, G.M., et al. 2002. Matrix metalloproteinases 
2 and 9 work in concert to produce aortic aneu-
rysms. J. Clin. Invest. 110:625–632. doi:10.1172/
JCI200215334.
 34. Shireman, P.K., et al. 1997. Elevations of tissue-type 
plasminogen activator and differential expression 
of urokinase-type plasminogen activator in dis-
eased aorta. J. Vasc. Surg. 25:157–164.
 35. Carmeliet, P., et al. 1997. Urokinase-generated 
plasmin activates matrix metalloproteinases dur-
ing aneurysm formation. Nat. Genet. 17:439–444.
 36. Huaux, F., Liu, T., McGarry, B., Ullenbruch, M., and 
Phan, S.H. 2003. Dual roles of IL-4 in lung injury 
and fibrosis. J. Immunol. 170:2083–2092.
 37. Corcoran, M.L., Stetler-Stevenson, W.G., Brown, 
P.D., and Wahl, L.M. 1992. Interleukin 4 inhibition 
of prostaglandin E2 synthesis blocks interstitial 
collagenase and 92-kDa type IV collagenase/gela-
tinase production by human monocytes. J. Biol. 
Chem. 267:515–519.
 38. Lanone, S., et al. 2002. Overlapping and enzyme-spe-
cific contributions of matrix metalloproteinases-9   
and -12 in IL-13–induced inflammation and remod-
eling. J. Clin. Invest. 110:463–474. doi:10.1172/
JCI200214136.
 39. Furukawa, Y., et al. 1999. Interleukin-10 (IL-10) aug-
ments allograft arterial disease: paradoxical effects 
of IL-10 in vivo. Am. J. Pathol. 155:1929–1939.
 40. Wang, Z., et al. 2000. Interferon gamma induction 
of pulmonary emphysema in the adult murine 
lung. J. Exp. Med. 192:1587–1600.
 41. Shapiro, S.D., Campbell, E.J., Kobayashi, D.K., and 
Welgus, H.G. 1990. Immune modulation of metal-
loproteinase production in human macrophages. 
Selective pretranslational suppression of intersti-
tial collagenase and stromelysin biosynthesis by 
interferon-gamma. J. Clin. Invest. 86:1204–1210.
 42. Xie, B., et al. 1994. Localization of accessory path-
ways from the 12-lead electrocardiogram using a 
new algorithm. Am. J. Cardiol. 74:161–165.
 43. Kumar, R., Dong, Z., and Fidler, I.J. 1996. Dif-
ferential regulation of metalloelastase activity in 
murine peritoneal macrophages by granulocyte-
macrophage colony-stimulating factor and mac-
rophage colony-stimulating factor. J. Immunol. 
157:5104–5111.
 44. Gupta, S., et al. 1997. IFN-gamma potentiates ath-
erosclerosis in ApoE knock-out mice. J. Clin. Invest. 
99:2752–2761.
 45. Nagano, H., et al. 1997. Interferon-gamma defi-
ciency prevents coronary arteriosclerosis but not 
myocardial rejection in transplanted mouse hearts. 
J. Clin. Invest. 100:550–557.
 46. Presti, R.M., Pollock, J.L., Dal Canto, A.J., O’Guin, 
A.K., and Virgin, H.W., 4th. 1998. Interferon 
gamma regulates acute and latent murine cyto-
megalovirus infection and chronic disease of the 
great vessels. J. Exp. Med. 188:577–588.
 47. Weck, K.E., et al. 1997. Murine gamma-herpesvi-
rus 68 causes severe large-vessel arteritis in mice 
lacking interferon-gamma responsiveness: a new 
model for virus-induced vascular disease. Nat. Med. 
3:1346–1353.
 48. Huang, S., et al. 1993. Immune response in mice 
that lack the interferon-gamma receptor. Science. 
259:1742–1745.
 49. Shichiri, M., and Hirata, Y. 2001. Antiangiogenesis 
signals by endostatin. FASEB J. 15:1044–1053.
 50. Nakajima, K., Powers, J.C., Ashe, B.M., and Zim-
merman, M. 1979. Mapping the extended substrate 
binding site of cathepsin G and human leukocyte 
elastase. Studies with peptide substrates related to 
the alpha 1-protease inhibitor reactive site. J. Biol. 
Chem. 254:4027–4032.
 51. Shimizu, K., Schonbeck, U., Mach, F., Libby, P., and 
Mitchell, R.N. 2000. Host CD40 ligand deficiency 
induces long-term allograft survival and donor-
specific tolerance in mouse cardiac transplanta-
tion but does not prevent graft arteriosclerosis.   
J. Immunol. 165:3506–3518.